Physician profile
Arlene Hady Ortega
NPI 1740708700
$135,058.56
in general payments reported to CMS, 2019-2025
24 companies · $72K in 2025
The $72K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $329 · 2022: $362 · 2023: $22K · 2024: $40K · 2025: $72K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $92K · Travel and Lodging: $25K · Food and Beverage: $9,394 · Consulting Fee: $8,047 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $92,042.50 |
| Travel and Lodging | $24,754.02 |
| Food and Beverage | $9,394.09 |
| Consulting Fee | $8,046.50 |
| Education | $131.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $47,362.60 | 2021-2025 | Qinlock |
| Astellas Pharma US INC | $33,912.50 | 2024-2025 | Vyloy |
| Astrazeneca Pharmaceuticals Lp | $28,140.80 | 2023-2025 | Imfinzi, Enhertu, Lynparza |
| Jazz Pharmaceuticals INC. | $12,058.64 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $6,895.00 | 2024-2025 | Fruzaqla |
| Astellas Pharma Global Development | $3,829.10 | 2024 | Vyloy |
| Pfizer INC. | $330.85 | 2023 | |
| Daiichi Sankyo INC. | $305.40 | 2021-2023 | |
| Incyte Corporation | $295.81 | 2022-2025 | Jakafi |
| Eisai INC. | $253.54 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $244.88 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $227.02 | 2024 | Libtayo |
| Abbvie INC. | $210.13 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $152.58 | 2023-2024 | Onivyde |
| Janssen Biotech, INC. | $122.06 | 2024 | Rybrevant |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $120.99 | 2023 | Optune |
| Puma Biotechnology, INC. | $118.57 | 2024 | |
| Springworks Therapeutics, INC. | $114.58 | 2025 | |
| Stemline Therapeutics INC. | $109.36 | 2024 | Elzonris |
| Pharmacosmos Therapeutics INC. | $108.10 | 2025 | Monoferric |
| Gilead Sciences, INC. | $46.58 | 2024 | |
| Fujifilm Healthcare Americas Corporation | $46.21 | 2023 | Utaswako Afp-L3 |
| Genentech USA, INC. | $31.37 | 2025 | Tecentriq |
| E.R. Squibb & Sons, L.L.C. | $21.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arlene Ortega listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.